Annual General Meeting of Kuros Biosciences approves all resolutions
Kuros Biosciences (SIX:KURN), a leader in next generation bone graft technologies, held its Annual General Meeting today…
Kuros Biosciences (SIX:KURN), a leader in next generation bone graft technologies, held its Annual General Meeting today…
 Financial highlights Direct MagnetOs sales grew by 163% to CHF 31.7 million in 2023, climbing from CHF 12.1 million…
Kuros Biosciences (“Kuros” or “the Company”), a leader in next generation bone graft technologies, today announced it wi…
 MagnetOs™ GranulÂes becomes the third product in the MagnetOs portfolio to receive FDA clearance to market for inter…
 MagnetOs is the first open fibrillar collagen matrix bone graft substitute to receive clearance to market for interb…
 In the MAXA trial, standalone MagnetOs outperformed the gold standard autograft by 73% in posterior spinal fusion in…
. New level 1 data from the MAXA Clinical Trial comparing standalone MagnetOs to the gold standard autograft in the ch…
Core One Labs Inc. (CSE: COOL), (OTCQB: CLABF), (FWB: LD6, WKN: A3CSSU) (das „Unternehmen“ oder „Core One“) freut sich,…
Asep Medical Holdings Inc. („Asep Inc.“ oder das „Unternehmen“) (CSE: ASEP) (OTCQB: SEPSF) (FWB: JJ8) freut sich bekannt…
First investigational trial of drug-biologic bone graft for spinal fusion 50 patients have been enrolled in the Phase 2…